TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females in generally good health aged 18-80 years with moderate to severe acute low back pain.~* Current acute low back pain episode within 48h prior to study entry.~* Pain must be moderate to severe following incident~Exclusion Criteria:~* Chronic low back pain~* Ongoing or history of alcohol or drug abuse~* Body Mass Index greater 39~* Treatment within the last 3 weeks with monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds; neuroleptics; selective serotonin reuptake inhibitors~* Known history or symptoms suspicious for cancer~* Significant renal or liver disease~* Spinal surgery within 1 year of study entry.~* Subjects who are pregnant or lactating.~* Subjects with unstable medical disease.~* Subjects who have received treatment with an investigational product/device with 30 days prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)~* Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory~* Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma~* Evidence of at least one measurable lesion as detected by radiological or photographic methods~* Adequate bone marrow, organ function, cardiac and laboratory parameters~* Normal functioning of daily living activities~Exclusion Criteria:~* Any untreated CNS metastases~* Uveal or mucosal melanoma~* History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO~* Patients with washout period \< 6 weeks from the last dose of ipilimumab or other immunotherapy.~* Previous systemic chemotherapy for unresectable locally advanced or metastatic melanoma.~* History of Gilbert's syndrome~* Prior therapy with a MEK- inhibitor~* Impaired cardiovascular function or clinically significant cardiovascular diseases~* Uncontrolled arterial hypertension despite medical treatment~* HIV positive or active Hepatitis A or B~* Impairment of gastrointestinal function~* Patients who have undergone major surgery or radiotherapy ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;~* Patients with neuromuscular disorders that are associated with elevated CK.~* Pregnant or nursing (lactating) women~* Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEK162 (Type: EXPERIMENTAL): None
- Dacarbazine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with the diagnosis of facial acne vulgaris having comedones, papules, pustules (≤5), or nodules (≤2) or Investigator's static global assessment score ≤4~* Treatment naïve patients or patients who had not taken topical anti-acne medications in last 14 days, systemic antibiotics in last 30 days, oral retinoids in last 12 months~Exclusion Criteria:~* Very severe acne vulgaris (Investigator's static global assessment score \>4)~* Any skin disorder that might interfere with the diagnosis or evaluation of acne vulgaris~* Known hypersensitivity to retinoids and clindamycin~* Any uncontrolled systemic disease or any cosmetic or surgical procedures complementary to the treatment of acne in the preceding 15 days~* Patients who were on oral contraceptive pills in last 12 weeks~* Pregnant and nursing women

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Tazarotene group (Type: EXPERIMENTAL): This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
- Adapalene group (Type: ACTIVE_COMPARATOR): This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide and Peripheral Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of type 2 diabetes within at least 6 months~* peripheral arterial disease documented within al least 1 year by doppler ultrasound, angio-CT or arteriography~* peripheral transcutaneous oxygen pressure between 30 and 49 mmHg on anterior and/or posterior tibial arteries~* Hba1c 6,5-8%~* treatment of diabetes with metformin, insulin and/or sulfonylurea~Exclusion Criteria:~* diagnosis of type 1 diabetes~* current treatment with GLP-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase -4 (DPP-4) inhibitors~* GLP-1RAs allergy or intolerance~* participation to other clinical studies~* history of pancreatitis, thyroid disease, diabetic gastroparesis or inflammatory bowel disease~* current or planned pregnancy~* acute myocardial infarction and/or acute cerebrovascular disease within 14 days from the screening visit~* planned revascularization procedure~* renal function with estimated glomerular filtration rate (eGFR) below 15 ml/min~* history of cancer and/or oncological treatment within 5 years from the screening visit~* current treatment with corticosteroids~* psychiatric or other clinical conditions which may interfere with the study

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide group (Type: EXPERIMENTAL): Patients in this arm will receive liraglutide, according to the current clinical practice.
- Control group (Type: OTHER): Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants as established by medical history and clinical examination before entering the study.~2. Age: 6-8 weeks at the time of enrollment.~3. Parental ability and willingness to provide informed consent.~4. Parent who intends to remain in the area with the child during the study period.~Exclusion Criteria:~1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment.~2. Acute disease at the time of enrollment (temporary exclusion)~3. Concurrent participation in another clinical trial at any point throughout the entire time frame for this study~4. History of congenital abdominal disorders, intussusception, or abdominal surgery.~5. Known or suspected impairment of immunological function based on medical history and physical examination.~6. History of any neurologic disorders or seizures.~7. Any medical condition in the parents / infant which, in the judgment of the Investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parents' ability to give informed consent.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- LBRV-PV Lot A (Type: EXPERIMENTAL): The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
- LBRV-PV Lot B (Type: EXPERIMENTAL): The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
- LBRV-PV Lot C (Type: EXPERIMENTAL): The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
- ROTASIIL (Type: ACTIVE_COMPARATOR): The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RELAX: A Mobile Application Suite Targeting Obesity and Stress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI of 27-45~* Currently use an Android smartphone~* Have cell phone connectivity at home and work~* Uses a smartphone every day~Exclusion Criteria:~* Under the age of 18 and over the age of 65;~* BMI under 27 or over 45;~* Not interested in losing weight;~* Does not currently own a smartphone;~* Smartphone type and/or version not meeting app requirements;~* No phone connectivity at home and work;~* Unable to walk unaided for ¼ mile without stopping;~* Has a condition that precludes dietary changes (i.e. ulcerative colitis, Crohn's disease, active diverticulitis, renal disease);~* On a medication affecting weight;~* Type 1 or 2 diabetes;~* Had gastric bypass surgery;~* Had or plans to have gastric bypass surgery during the study period;~* Pregnant/lactating;~* Has bipolar disorder, substance abuse, bulimia, or severe depression;~* Lost 5% or more body weight in the last 3 months;~* Has not experienced emotional eating over the last week;~* On medication affecting weight;~* Has concerns about being audiotaped;~* Prisoner;~* Unable to provide consent; or~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Comprehensive Dietary Self-Monitoring (Type: ACTIVE_COMPARATOR): The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
- Simple Dietary Self-Monitoring (Type: ACTIVE_COMPARATOR): The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Is healthy (based on a review of medical history and physical examination) in the clinical judgement of the investigator~* Has a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent.~Exclusion Criteria:~* Has a history of invasive pneumococcal disease (IPD; positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease.~* Has a known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV), any component of the licensed pediatric vaccines to be administered concomitantly in the study, or any diphtheria toxoid-containing vaccine.~* Has any contraindication to the concomitant study vaccines being administered in the study.~* Had a recent febrile illness (rectal temperature ≥38.1°C \[=100.5°F\] or axillary temperature ≥37.8°C \[=100.0°F\]) occurring within 72 hours prior to receipt of study vaccine.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants receive 4 total 0.5 mL intramuscular (IM) vaccinations at \~2, 4, 6, and 12 to 15 months of age. Participants will receive other vaccinations (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants receive 4 total 0.5 mL IM vaccinations at \~2, 4, 6, and 12 to 15 months of age. Participants will also receive other vaccines (i.e., RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, M-M-R II™, VARIVAX™, and HIBERIX™) as part of their vaccination schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low Plasma Mannose Binding Lectin (p-MBL) Level is a Risk Factor for Recurrent Pregnancy Loss (RPL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Women admitted to the Centre for Recurrent Pregnancy Loss of Western Denmark January 2016 to March 2020~Exclusion Criteria:~* Less than 3 consecutive pregnancy losses~* Significant uterine malformation on hydrosonography or hysteroscopy~* Significant chromosomal abnormalities~* Abnormal menstrual cycle length (\<22 or \>35 days) or irregular cycle~* Pregnancy at first meeting in the Recurrent Miscarriage Clinic~* Age \<18 and \>45 years

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Study sample (Type: None): In total, 267 women with unexplained recurrent pregnancy loss was included.~Only patients with a history of 3 or more consecutive spontaneous pregnancy losses are included. Both biochemical and clinical losses documented in hospital records are accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social reasons are not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (\<22 and \>35 days interval), and/or no MBL measurement.
- Reference Group (Type: None): The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information. After informed approval, all controls had an extra blood sample taken, which was analysed for p-MBL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are able to provide informed consent~* Age 20 years and older~* Diagnosis of stage II to III breast cancer~* Patients who had undergone surgery for breast cancer treatment.~* Planning to receive anthracycline -based adjuvant chemotherapy~* Have adequate bone marrow, liver, and renal function~* ECOG ≦1~* Willing and able to complete quality of life questionnaires.~Exclusion Criteria:~* Pregnancy or lactating women.~* Baseline BFI score \>3.~* History of chronic fatigue syndrome, uncontrolled active infection, active cardiac disease, poor controlled hypertension or diabetes mellitus, any serious medical condition, psychiatric illness, and regular steroid therapy as determined by investigators.~* History of previous breast cancer or other malignancy within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer.~* Known severe allergy to Astragalus membranaceus or its mayor extracts (polysaccharides).

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Placebo
- Treatment (Type: EXPERIMENTAL): Astragalus polysaccharides 500 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Daily Atropine Versus Weekend Atropine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \< 7 years~* Able to measure surrounded single optotype visual acuity using the ATS single-surround HOTV protocol (this will in effect exclude all patients \<2 years old and many \<3 years old)~* Amblyopia associated with strabismus, anisometropia, or both~* If anisometropia is present (as per protocol definition), refractive error corrected with spectacles for a minimum of 4 weeks~* Visual acuity in the amblyopic eye \< 20/40 and \>20/80~* Visual acuity in the sound eye \> 20/40 and inter-eye acuity difference \>3 logMAR lines~Exclusion Criteria:~* Amblyopia treatment (other than spectacles) in the past month and no more than one month of amblyopia treatment in the past 6 months~* Myopia more than a spherical equivalent of -6.00 D in the amblyopic eye~* Myopia more than a spherical equivalent of -0.50 D in the sound eye

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Undiagnosed COPD and Asthma Population Study (UCAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects at least 18 years old;~* Subjects who score \> or = to 6 points on The Asthma Screening Questionnaire or \> 19.5 points on The COPD Diagnostic Questionnaire;~* Subjects who have given written informed consent to participate in this trial in accordance with local regulations;~* Subjects able to perform pre and post bronchodilator spirometry to measure lung function;~Additional Inclusion Criteria for RCT:~Those subjects who have undiagnosed airflow obstruction (i.e. Asthma will be diagnosed in subjects with airflow obstruction whose FEV1 improves by \> 12% and 200 ml after bronchodilator and COPD will be diagnosed in subjects who do not have a significant bronchodilator response and who exhibit persistent airflow obstruction post bronchodilator) will be asked to consent and participate in the RCT.~Exclusion Criteria:~* Subjects who report a previous physician diagnosis of asthma.~* Subjects who report a previous physician diagnosis of COPD~* Subjects with any of the following conditions within the past 3 months: Heart attack or hospitalization for other heart problems; Stroke; Aortic or cerebral aneurysm; Detached retina or eye surgery~* Subjects who are in the third trimester of pregnancy~* Subjects involved in another interventional trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhanced Care (Type: ACTIVE_COMPARATOR): Treatment strategy using evidence-based guidelines for asthma or COPD
- Standard of Care (Type: PLACEBO_COMPARATOR): Spirometry result sent to family MD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete